KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 62 days ( 0 % )
Last Price $1.48 0 %
High/ Low $1.48 - $1.48 0%
Chg 7 Days N/A $1.48 $1.48
Chg 30 Days N/A $1.48 $1.48
Chg 12 mos -46.18 % $2.75 $1.48
Trend - 3 mos N/A Width: 0 %
Trend - 12 mos -6.79 % Width: 258.50 %
Pred. range - 3 mos N/A - N/A -100.00 % - -100.00 %
Pred. range - 12 mos $0.619 - $2.22 -58.15 % - 50.02 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Sell May 19, 2023 - 71 days
Long MA avg 12 mos Sell May 30, 2023 - 65 days
Short/Long MA avg 12 mos Sell Jun 21, 2023 - 50 days
Pivot Short Buy Aug 29, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About TCR2 Therapeutics Inc.

TCR2 Therapeutics. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal... TCRR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT